Amorphous drug-polyanion nanoplex represents an effective solubility enhancement strategy of weakly-basic poorly-soluble drugs. While dextran sulfate (DXT) was chosen in most studies as the polyanion for nanoplex formation, drug-DXT nanoplex demonstrated poor long-term physical stability for drugs with high crystallization propensity, such as ciprofloxacin (CIP). Herein we hypothesized that amorphous form stability of CIP nanoplex could be improved by substituting DXT with carboxymethyl cellulose (CMC) known for its crystallization inhibiting activity. The optimal preparation condition of the CIP-CMC nanoplex was determined by investigating the effects of CMC/CIP charge ratio and pH on the resultant nanoplex's physical characteristics and p...
Objectives: To carry out a proof-of-concept study on the development of dual-drug amorphous nanopart...
High-payload amorphous drug–polysaccharide nanoparticle complex (or nanoplex in short) represents a ...
Objectives: To carry out a proof-of-concept study on the development of dual-drug amorphous nanopart...
Amorphous drug-polyelectrolyte nanoparticle complex (or nanoplex in short) has emerged as a highly a...
Amorphization, typically in the form of amorphous solid dispersion (ASD), represents a well-establis...
In spite of various contemporary medicinal approaches developed, there are still more than 40% of dr...
In spite of various contemporary medicinal approaches developed, there are still more than 40% of dr...
The dissolution rate and solubility of poorly soluble drugs can be enhanced by formulating them into...
Objective: The objective of this study is to develop a new solubility enhancement strategy of anti- ...
Amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex) had emerged as an ideal supers...
Amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex) had emerged as an ideal supers...
Poor bioavailability of the broad spectrum antibiotic ciprofloxacin (CIP) is caused by its narrow ab...
Poor bioavailability of the broad spectrum antibiotic ciprofloxacin (CIP) is caused by its narrow ab...
Ciprofloxacin (CIP) is a poorly soluble drug that also displays poor permeability. Attempts to impro...
High-payload amorphous drug–polysaccharide nanoparticle complex (or nanoplex in short) represents a ...
Objectives: To carry out a proof-of-concept study on the development of dual-drug amorphous nanopart...
High-payload amorphous drug–polysaccharide nanoparticle complex (or nanoplex in short) represents a ...
Objectives: To carry out a proof-of-concept study on the development of dual-drug amorphous nanopart...
Amorphous drug-polyelectrolyte nanoparticle complex (or nanoplex in short) has emerged as a highly a...
Amorphization, typically in the form of amorphous solid dispersion (ASD), represents a well-establis...
In spite of various contemporary medicinal approaches developed, there are still more than 40% of dr...
In spite of various contemporary medicinal approaches developed, there are still more than 40% of dr...
The dissolution rate and solubility of poorly soluble drugs can be enhanced by formulating them into...
Objective: The objective of this study is to develop a new solubility enhancement strategy of anti- ...
Amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex) had emerged as an ideal supers...
Amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex) had emerged as an ideal supers...
Poor bioavailability of the broad spectrum antibiotic ciprofloxacin (CIP) is caused by its narrow ab...
Poor bioavailability of the broad spectrum antibiotic ciprofloxacin (CIP) is caused by its narrow ab...
Ciprofloxacin (CIP) is a poorly soluble drug that also displays poor permeability. Attempts to impro...
High-payload amorphous drug–polysaccharide nanoparticle complex (or nanoplex in short) represents a ...
Objectives: To carry out a proof-of-concept study on the development of dual-drug amorphous nanopart...
High-payload amorphous drug–polysaccharide nanoparticle complex (or nanoplex in short) represents a ...
Objectives: To carry out a proof-of-concept study on the development of dual-drug amorphous nanopart...